LMNB2 and neoplasm: Precise targeting of its key nodes, for instance, the SGK1-RIPK1-necroptosis axis, the LMNB2-PD-L1 axis, or specific immune cell subsets, is a new direction for overcoming immunotherapy resistance and inhibiting tumor metastasis in the future.